tiprankstipranks
Advertisement
Advertisement

NGEN Stock Latest News

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
The FlyNervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
8d ago
NGEN
NervGen Pharma initiated with an Outperform at Leerink
PremiumThe Fly
NervGen Pharma initiated with an Outperform at Leerink
9d ago
NGEN
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners
PremiumCompany Announcements
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners
20d ago
6K
NGEN
NervGen Pharma initiated with a Buy at TD Cowen
PremiumThe Fly
NervGen Pharma initiated with a Buy at TD Cowen
1M ago
NGEN
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
PremiumCompany Announcements
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
2M ago
6K
NGEN
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
PremiumCompany AnnouncementsNervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
2M ago
NGEN
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
Premium
Company Announcements
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
2M ago
6K
NGEN
NervGen Pharma files $250M mixed securities shelf
Premium
The Fly
NervGen Pharma files $250M mixed securities shelf
2M ago
NGEN
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
PremiumThe Fly
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
2M ago
NGEN
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
PremiumCompany Announcements
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
2M ago
6K
NGEN
NervGen Pharma 24M share Spot Secondary priced at $2.50
PremiumThe Fly
NervGen Pharma 24M share Spot Secondary priced at $2.50
2M ago
NGEN
NervGen Pharma secondary being re-offered at $2.50 per share
PremiumThe Fly
NervGen Pharma secondary being re-offered at $2.50 per share
2M ago
NGEN
NervGen Pharma announces common share offering, no amount given
PremiumThe FlyNervGen Pharma announces common share offering, no amount given
2M ago
NGEN
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
Premium
Company Announcements
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
2M ago
6K
NGEN
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
Premium
The Fly
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
2M ago
NGEN
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
PremiumCompany Announcements
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
2M ago
6K
NGEN
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
PremiumCompany Announcements
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
3M ago
6K
NGEN
NervGen Pharma appoints Keith Vendola as CFO
PremiumThe Fly
NervGen Pharma appoints Keith Vendola as CFO
3M ago
NGEN
NervGen Pharma initiated with a Buy at H.C. Wainwright
PremiumThe Fly
NervGen Pharma initiated with a Buy at H.C. Wainwright
3M ago
NGEN
NervGen Pharma initiated with a Buy at Lucid Capital
PremiumThe FlyNervGen Pharma initiated with a Buy at Lucid Capital
3M ago
NGEN
NervGen Pharma price target raised to $12 from $10 at Maxim
Premium
The Fly
NervGen Pharma price target raised to $12 from $10 at Maxim
4M ago
NGEN
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
Premium
Company Announcements
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
4M ago
NGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >